# PTIX (Protagenic Therapeutics, Inc.\new) - SEC EDGAR Financial Statements

> Protagenic Therapeutics, Inc.\new reported $0 in revenue and net income of $5.66M for the fiscal year ended March 31, 2026.

- Canonical: https://convexityos.com/fundamentals/PTIX
- Markdown: https://convexityos.com/fundamentals/PTIX.md
- SEC CIK: 0001022899
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 21, 2026, 05:13 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001022899&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2026 | $0 | Mar 31, 2026 |
| Operating Income | FY 2026 | -$2.68M | Operating profit |
| Net Income | FY 2026 | $5.66M | GAAP bottom line |
| Diluted EPS | FY 2026 | $3.13 | Split-adjusted |
| Free Cash Flow | FY 2026 | -$2.81M | Operating CF less CapEx |
| Cash & ST Investments | Sep 30, 2026 | $77K | Total debt: -- |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Revenue** | $0 | $0 | $0 | $0 | $0 | $0 | $0 | -- | -- | -- |
| Research & Development | $902K | $377K | $3.84M | $3.06M | $1.59M | $1.14M | $700K | $808K | $881K | $717K |
| Total Operating Expenses | $4.50M | $2.59M | $5.70M | $4.53M | $3.56M | $4.14M | $2.55M | $2.09M | $2.31M | $2.37M |
| **Operating Income** | -$4.50M | -$2.59M | -$5.70M | -$4.53M | -$3.56M | -$4.14M | -$2.55M | -$2.09M | -$2.31M | -$2.37M |
| **EBITDA** | -$4.45M | -- | -$5.65M | -$4.50M | -$3.56M | -- | -$2.55M | -$2.09M | -$2.31M | -$2.37M |
| Interest Income | -- | -- | $43K | $264K | $186K | $33K | $502 | -- | -- | -- |
| Interest Expense | -- | -- | -- | $108K | $137K | $497K | $246K | -- | -- | -- |
| Income Before Tax | $1.37M | -$3.59M | -$5.53M | -$5.00M | -$3.56M | -$4.52M | -$2.55M | -$1.75M | -$2.56M | -$2.26M |
| **Net Income** | $1.37M | -$3.59M | -$5.53M | -$5.00M | -$3.56M | -$4.52M | -$2.55M | -$1.75M | -$2.56M | -$2.26M |
| Basic EPS | $0.59 | -$0.67 | -$15.83 | -$16.11 | -$11.48 | -$69.47 | -$14.01 | -$9.52 | -$14.01 | -$12.32 |
| **Diluted EPS** | $0.59 | -$0.67 | -$15.83 | -$16.11 | -$11.48 | -$17.37 | -$14.01 | -$9.52 | -$14.01 | -$12.32 |
| Basic Shares Outstanding | 2.3M | 5.4M | 349.9K | 310.2K | 308.3K | 65.8K | 184.6K | 183.2K | 183.2K | 183.2K |
| Diluted Shares Outstanding | 2.3M | 5.4M | 349.9K | 310.2K | 308.3K | 263.1K | 184.6K | 183.2K | 183.2K | 183.2K |

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Revenue** | -- | -- | -- | -- | -- | -- | $0 | $0 |
| Research & Development | $27K | $110K | $81K | $154K | $218K | $394K | $880K | $135K |
| Total Operating Expenses | $671K | $961K | $120K | $925K | $1.11M | $1.21M | $1.45M | $401K |
| **Operating Income** | -$671K | -$961K | -$120K | -$925K | -$1.11M | -$1.21M | -$1.45M | -$401K |
| **EBITDA** | -$668K | -$953K | -$109K | -$913K | -$1.10M | -$1.20M | -$1.44M | -$401K |
| Interest Income | -- | -- | -- | -- | -- | -- | $8.1K | $9.0K |
| Income Before Tax | -$667K | -$964K | $5.08M | $2.21M | -$869K | -$5.06M | -$1.44M | -$850K |
| **Net Income** | -$667K | -$964K | $5.08M | $2.21M | -$869K | -$5.06M | -$1.44M | -$850K |
| Basic EPS | -$0.37 | -$0.53 | -- | $1.14 | -$0.47 | -$1.37 | -$2.75 | -$0.16 |
| **Diluted EPS** | -$0.37 | -$0.53 | -- | $1.14 | -$0.47 | -$1.37 | -$2.75 | -$0.16 |
| Basic Shares Outstanding | 1.8M | 1.8M | -- | 1.9M | 1.8M | 3.7M | 523.2K | 5.4M |
| Diluted Shares Outstanding | 1.8M | 1.8M | -- | 1.9M | 1.8M | 3.7M | 523.2K | 5.4M |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $1.51M | $15K | $1.84M | $1.29M | $215K | $541K | $671K | $799K | $362K | $400K |
| Short-Term Investments | -- | -- | -- | $2.77M | $7.76M | $9.83M | -- | -- | -- | -- |
| **Cash & Short-Term Investments** | $1.51M | $15K | $1.84M | $4.06M | $7.98M | $10.37M | $671K | $799K | $362K | $400K |
| Inventory | -- | $1.0K | -- | -- | -- | -- | -- | -- | -- | -- |
| **Total Current Assets** | $1.54M | $89K | $1.88M | $4.20M | $8.04M | $11.06M | $879K | $842K | $696K | $1.78M |
| Property, Plant & Equipment, Net | $15K | $60K | $73K | $123K | $1.8K | -- | -- | $296 | $611 | $1.0K |
| Intangible Assets | $2.09M | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| **Total Non-Current Assets** | $2.11M | $0 | $73K | $123K | $1.8K | $0 | $0 | $296 | $611 | $1.0K |
| **Total Assets** | $3.65M | $89K | $1.96M | $4.32M | $8.04M | $11.06M | $879K | $842K | $697K | $1.78M |
| Accounts Payable | $950K | $961K | -- | -- | -- | -- | -- | -- | -- | -- |
| Other Current Liabilities | $0 | $779K | -- | -- | -- | -- | -- | -- | -- | -- |
| **Total Current Liabilities** | $1.03M | $5.04M | $943K | $655K | $1.12M | $800K | $655K | $1.20M | $908K | $562K |
| **Total Non-Current Liabilities** | $0 | $0 | $0 | $0 | $0 | $318K | $1.37M | $279K | $0 | $0 |
| **Total Liabilities** | $1.03M | $5.04M | $943K | $655K | $1.12M | $1.12M | $2.03M | $1.48M | $908K | $562K |
| Common Stock | $182 | $54 | $52 | $444 | $434 | $432 | $1.0K | $1.0K | $1.0K | $1.0K |
| Retained Earnings | -$4.03M | -$5.40M | -$36.30M | -$30.78M | -$25.78M | -$22.22M | -$17.70M | -$15.15M | -$13.40M | -$10.84M |
| Accumulated Other Comp. Income | -- | -$130K | -$130K | -$114K | -$677K | -$248K | -$172K | -$172K | -$171K | -$168K |
| **Total Stockholders' Equity** | $2.62M | -$4.95M | -$3.32M | $3.67M | $6.92M | $9.94M | -$1.15M | -$634K | -$211K | $1.22M |
| Total Equity | $2.62M | -$4.95M | -$3.32M | $3.67M | $6.92M | $9.94M | -$1.15M | -$634K | -$211K | $1.22M |

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $77K | $566K | $1.51M | $2.21M | $2.72M | $15K | $1.84M | $1.06M |
| **Cash & Short-Term Investments** | $77K | $566K | $1.51M | $2.21M | $2.72M | $15K | $1.84M | $1.06M |
| Inventory | -- | -- | -- | $1.1K | $1.1K | $1.0K | -- | -- |
| **Total Current Assets** | $188K | $710K | $1.54M | $2.30M | $2.86M | $89K | $1.88M | $1.42M |
| Property, Plant & Equipment, Net | $3.3K | $6.2K | $15K | $39K | $51K | $60K | $73K | $86K |
| Intangible Assets | $2.08M | $2.08M | $2.09M | $2.09M | $2.09M | -- | -- | -- |
| **Total Non-Current Assets** | $2.08M | $2.09M | $2.11M | $2.13M | $2.14M | $0 | $73K | $86K |
| **Total Assets** | $2.27M | $2.80M | $3.65M | $4.43M | $5.00M | $89K | $1.96M | $1.51M |
| Accounts Payable | $1.07M | $1000K | $950K | $2.03M | $1.64M | $961K | -- | -- |
| Other Current Liabilities | -- | -- | $0 | $840K | $842K | $779K | -- | -- |
| **Total Current Liabilities** | $1.15M | $1.07M | $1.03M | $6.82M | $9.70M | $5.04M | $943K | $789K |
| **Total Non-Current Liabilities** | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| **Total Liabilities** | $1.15M | $1.07M | $1.03M | $6.82M | $9.70M | $5.04M | $943K | $789K |
| Common Stock | $182 | $182 | $182 | $195 | $195 | $54 | $52 | $481 |
| Retained Earnings | -$5.66M | -$4.99M | -$4.03M | -$9.11M | -$11.32M | -$5.40M | -$36.30M | -$34.75M |
| Accumulated Other Comp. Income | -- | -- | -- | -- | -- | -$130K | -$130K | -$130K |
| **Total Stockholders' Equity** | $1.12M | $1.72M | $2.62M | -$2.39M | -$4.70M | -$4.95M | -$3.32M | -$2.47M |
| Total Equity | $1.12M | $1.72M | $2.62M | -$2.39M | -$4.70M | -$4.95M | -$3.32M | -$2.47M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | $1.37M | -$3.59M | -$5.53M | -$5.00M | -$3.56M | -$4.52M | -$2.55M | -$1.75M | -$2.56M | -$2.26M |
| Depreciation & Amortization | $49K | -- | $50K | $28K | $30 | -- | $286 | $339 | $347 | $148 |
| Stock-Based Compensation | $419K | -- | $923K | $667K | $865K | $1.52M | $1.65M | $798K | $1.13M | $888K |
| Change in Inventory | -$26 | -$29 | -- | -- | -- | -- | -- | -- | -- | -- |
| Change in Payables | $1.04M | $182K | -- | -- | -- | -- | -- | -- | -- | -- |
| **Operating Cash Flow** | -$2.81M | -$1.77M | -$4.22M | -$3.70M | -$1.99M | -$2.80M | -$1.35M | -$488K | -$1.07M | -$1.38M |
| Capital Expenditure | -$3.3K | -- | -- | -$150K | -$1.8K | -- | -- | -- | -- | -- |
| **Free Cash Flow** | -$2.81M | -- | -- | -$3.85M | -$2.00M | -- | -- | -- | -- | -- |
| Purchases of Investments | -- | -- | -$297K | -$2.76M | -$34K | -$10.40M | -- | -- | -- | -- |
| **Investing Cash Flow** | $630K | -- | $2.80M | $4.78M | $1.60M | -$9.91M | -- | $250K | $1.05M | -$1.29M |
| Common Stock Issued | $395K | $200 | -- | -- | -- | -- | -- | -- | -- | -- |
| **Financing Cash Flow** | $3.87M | $1.81M | $1.96M | -- | -- | $12.58M | $1.22M | $670K | -- | -- |
| **Net Change in Cash** | $1.70M | $40K | $551K | $1.07M | -$326K | -$130K | -$128K | $436K | -$37K | -$2.70M |

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$667K | -$964K | $5.08M | $2.21M | -$869K | -$5.06M | -$1.44M | -$850K |
| Depreciation & Amortization | $2.9K | $8.3K | $12K | $13K | $13K | $13K | $13K | $0 |
| Stock-Based Compensation | $62K | $67K | $92K | $96K | $106K | $125K | $236K | $245K |
| Change in Inventory | -- | -- | $10 | $1 | $20 | -$57 | -- | -- |
| Change in Payables | $69K | $50K | $827K | $389K | -$442K | $265K | -- | -- |
| **Operating Cash Flow** | -$489K | -$944K | $266K | $74K | -$1.40M | -$1.75M | -$1.07M | -$820K |
| Purchases of Investments | -- | -- | -- | -- | -- | -- | -- | $0 |
| **Investing Cash Flow** | -- | -- | -$313K | $0 | $0 | $943K | -- | $0 |
| Common Stock Issued | -- | -- | $0 | $0 | $0 | $395K | -- | -- |
| **Financing Cash Flow** | -- | -- | -$534K | -$584K | -$15K | $5.01M | $103K | -- |
| **Net Change in Cash** | -$489K | -$944K | -$582K | -$510K | -$1.41M | $4.20M | -$966K | $783K |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | 52.2% | -- | -- | -136.3% | -51.4% | -45.5% | -- | -- | -- | -185.3% |
| Return on Assets (ROA) | 37.5% | -4031.6% | -282.5% | -115.7% | -44.2% | -40.9% | -289.9% | -207.9% | -367.0% | -126.9% |
| Current Ratio | 1.50x | 0.02x | 2.00x | 6.41x | 7.18x | 13.83x | 1.34x | 0.70x | 0.77x | 3.17x |
| Quick Ratio | 1.46x | 0.02x | 1.95x | 6.19x | 7.12x | 12.97x | 1.02x | 0.67x | 0.40x | 0.71x |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | 506.4% | 316.9% | 52.2% | -- | -- | -- | -- | -- |
| Return on Assets (ROA) | 249.3% | 195.3% | 37.5% | -116.4% | -164.3% | -- | -3588.4% | -178.0% |
| Current Ratio | 0.16x | 0.66x | 1.50x | 0.34x | 0.29x | -- | 0.02x | 2.00x |
| Quick Ratio | 0.07x | 0.53x | 1.46x | 0.34x | 0.29x | -- | 0.02x | 1.95x |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
